Af­ter ear­ly hic­cups in man­u­fac­tur­ing, Ad­verum out­lines plans for com­mer­cial gene ther­a­py plant in North Car­oli­na hub

Af­ter some ear­ly hic­cups in its man­u­fac­tur­ing pro­ce­dures for its gene ther­a­py drug tar­get­ing wet age-re­lat­ed mac­u­lar de­gen­er­a­tion, Cal­i­for­nia biotech Ad­verum has ad­dressed those con­cerns and is prim­ing the pump for a com­mer­cial launch.

The oc­u­lar and oth­er rare dis­ease-fo­cused gene ther­a­py com­pa­ny will in­vest $80 mil­lion in a new cGMP man­u­fac­tur­ing fa­cil­i­ty in North Car­oli­na’s bustling Re­search Tri­an­gle Park that by 2023 will be ready to man­u­fac­ture com­mer­cial sup­ply of AD­VM-022, Ad­verum’s in­trav­it­re­al ther­a­peu­tic, the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER